Next Generation Pneumococcal Disease Protection
Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine, PCV15, NDC: 00006-4329-03 is the advanced, FDA-approved solution for the prevention of invasive disease caused by Streptococcus pneumoniae in both adults and children. Each prefilled 0.5mL syringe delivers powerful, broad-spectrum protection against 15 key pneumococcal serotypes, offering a longer and stronger immune response compared to earlier-generation vaccines. Supplied in convenient 10-count boxes, Vaxneuvance is the preferred choice for clinics, health systems, pharmacies, and pediatric offices committed to top-tier patient immunization and public health.
Features & Benefits
-
Enhanced 15-Valent Pneumococcal Coverage: Immunizes against 15 clinically relevant Streptococcus pneumoniae serotypes, expanding on traditional Prevnar and Pneumovax coverage for broader defense.
-
Pre-filled 0.5mL Syringes: Ready to administer, ensuring dosing accuracy, convenience, and safety for healthcare professionals.
-
FDA Approved for Adults and Children: Indicated for immunization of infants, children, adolescents, and adults for comprehensive age group protection.
-
Helps Prevent Serious Pneumococcal Diseases: Significantly reduces risk of invasive pneumococcal diseases (IPD) including pneumonia, bacteremia, meningitis, and septicemia.
-
Supports CDC and ACIP Immunization Schedules: Fully meets CDC and ACIP recommendations for routine and high-risk populations, including seniors and immunocompromised.
-
Safe & Well-Tolerated: Proven high safety profile with minimal adverse events in clinical studies.
-
10 per Box – Ideal for Clinics & Pharmacies: Optimized for high-throughput settings with easy inventory management.
-
Refrigerator Stable: Convenient cold storage for effortless integration into existing vaccine supplies.
Indications & Patient Benefits
Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) is indicated for:
- Children as young as 6 weeks through adulthood
- Adults aged 18 years and older, especially those 65+ or with chronic health conditions (e.g., diabetes, heart disease, COPD, asthma)
- Individuals with immunocompromising conditions or functional/anatomic asplenia
- Anyone at increased risk for pneumococcal pneumonia, bacteremia, meningitis, and severe pneumococcal complications
Key advantages for patients:
- Reduces risk of life-threatening pneumococcal infections
- Prevents antibiotic-resistant strains of pneumonia
- Links to improved long-term respiratory and overall health
- Reduces hospitalizations, healthcare costs, and caregiver burden
Why Choose Vaxneuvance (PCV15) for Your Clinic?
Vaxneuvance PCV15 delivers advanced, next-generation protection against pneumococcal disease—with robust immune response, broad serotype coverage, exceptional safety, and ease of use in all healthcare settings. Trusted by pediatricians, internists, geriatricians, and immunizers nationwide, Vaxneuvance helps meet and exceed public health goals for pneumococcal disease prevention.
Product Specifications
-
Name: Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine)
-
Dosage Form: 0.5mL pre-filled syringe
-
Quantity: 10 syringes per box
-
Age Indication: 6 weeks and above (children, adults, seniors)
-
Administration: Intramuscular injection (IM)
-
Storage: Refrigerate (2°C to 8°C/36°F to 46°F)
-
Manufacturer: [Insert Manufacturer, e.g., Merck & Co.]
-
NDC: 00006-4329-03
Stock your facility with the most up-to-date, CDC-recommended, FDA-approved protection—Vaxneuvance Vaccine (Pneumococcal 15-valent Conjugate Vaccine) 0.5mL Syringes x 10/Box. Safeguard your community, improve outcomes, and prevent the spread of serious pneumococcal infections.
Available for immediate order. Wholesale pricing for clinics, health systems, and pharmacies. Contact us for more information or bulk purchases!
